347 related articles for article (PubMed ID: 6341476)
21. Common acquired melanocytic nevi, dysplastic melanocytic nevi and malignant melanomas: an image analysis cytometric study.
Bruijn JA; Berwick M; Mihm MC; Barnhill RL
J Cutan Pathol; 1993 Apr; 20(2):121-5. PubMed ID: 8320355
[TBL] [Abstract][Full Text] [Related]
22. The initial steps of tumor progression in melanocytic lineage: a histochemical approach.
Wollina U; Kilian U; Henkel U; Schaarschmidt H; Knopf B
Anticancer Res; 1991; 11(4):1405-14. PubMed ID: 1746897
[TBL] [Abstract][Full Text] [Related]
23. Atypical melanocytic nevi of the genital type with a discussion of reciprocal parenchymal-stromal interactions in the biology of neoplasia.
Clark WH; Hood AF; Tucker MA; Jampel RM
Hum Pathol; 1998 Jan; 29(1 Suppl 1):S1-24. PubMed ID: 9445124
[TBL] [Abstract][Full Text] [Related]
24. Cutaneous melanocytic lesions: selected problem areas.
Wick MR; Patterson JW
Am J Clin Pathol; 2005 Dec; 124 Suppl():S52-83. PubMed ID: 16468418
[TBL] [Abstract][Full Text] [Related]
25. Cell kinetics of melanocytes in common and dysplastic nevi and in primary and metastatic cutaneous melanoma.
Urso C; Bondi R; Balzi M; Scubla E; Mauri P; Becciolini A; Tarocchi S; Vallecchi C
Pathol Res Pract; 1992 Apr; 188(3):323-9. PubMed ID: 1625997
[TBL] [Abstract][Full Text] [Related]
26. Dysplastic nevus in histologic contiguity with acquired nonfamilial melanoma. Clinicopathologic experience in a 100-bed hospital.
Duray PH; Ernstoff MS
Arch Dermatol; 1987 Jan; 123(1):80-4. PubMed ID: 3800426
[TBL] [Abstract][Full Text] [Related]
27. Origin of cutaneous melanoma in a congenital dysplastic nevus spilus.
Rhodes AR; Mihm MC
Arch Dermatol; 1990 Apr; 126(4):500-5. PubMed ID: 2321995
[TBL] [Abstract][Full Text] [Related]
28. Ex vivo quality-switched ruby laser irradiation of cutaneous melanocytic lesions: persistence of S-100-, HMB-45- and Masson-positive cells.
Kopera D; Hohenleutner U; Stolz W; Landthaler M
Dermatology; 1997; 194(4):344-50. PubMed ID: 9252755
[TBL] [Abstract][Full Text] [Related]
29. Malignant melanoma and nevocellular nevi. Histogenesis and relationships. Fluorescence-microscopic and catamnestic photographic studies.
Paul E
Norm Pathol Anat (Stuttg); 1984; 48():1-112. PubMed ID: 6701085
[TBL] [Abstract][Full Text] [Related]
30. Fine structural and immunohistochemical properties of dysplastic melanocytic nevi: comparison with malignant melanoma.
Jimbow K; Horikoshi T; Takahashi H; Akutsu Y; Maeda K
J Invest Dermatol; 1989 May; 92(5 Suppl):304S-309S. PubMed ID: 2715663
[TBL] [Abstract][Full Text] [Related]
31. Dysplastic nevi in relation to superficial spreading melanoma.
Titus-Ernstoff L; Barnhill RL; Duray PH; Ernstoff MS; Kirkwood JM
Cancer Epidemiol Biomarkers Prev; 1993; 2(2):99-101. PubMed ID: 8467253
[TBL] [Abstract][Full Text] [Related]
32. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
33. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma.
Clark WH; Elder DE; Guerry D; Epstein MN; Greene MH; Van Horn M
Hum Pathol; 1984 Dec; 15(12):1147-65. PubMed ID: 6500548
[TBL] [Abstract][Full Text] [Related]
34. Common acquired melanocytic nevi, melanocytic dysplasia and malignant melanoma. A morphometric study.
Santucci M; Urso C; Giannini A; Bondi R
Appl Pathol; 1989; 7(2):111-5. PubMed ID: 2730799
[TBL] [Abstract][Full Text] [Related]
35. The presence of dysplastic nevus remnants in malignant melanomas. A population-based study of 551 malignant melanomas.
Hastrup N; Osterlind A; Drzewiecki KT; Hou-Jensen K
Am J Dermatopathol; 1991 Aug; 13(4):378-85. PubMed ID: 1928622
[TBL] [Abstract][Full Text] [Related]
36. Nevi, other than dysplastic and Spitz nevi.
Cochran AJ; Bailly C; Paul E; Dolbeau D
Semin Diagn Pathol; 1993 Feb; 10(1):3-17. PubMed ID: 8506415
[TBL] [Abstract][Full Text] [Related]
37. HMB-45 staining of dysplastic melanocytic nevi in melanoma risk groups.
Ahmed I; Piepkorn M; Goldgar DE; Cannon-Albright LA; Meyer LJ; Skolnick MH; Zone JJ
J Cutan Pathol; 1991 Aug; 18(4):257-60. PubMed ID: 1939784
[TBL] [Abstract][Full Text] [Related]
38. Interleukin (IL)-1 alpha- and -1 beta-, IL-6-, and tumor necrosis factor-alpha-like immunoreactivities in human common and dysplastic nevocellular nevi and malignant melanoma.
Ahmed AA; Nordlind K; Hedblad M; Lagerholm B; Schultzberg M; Lidén S
Am J Dermatopathol; 1995 Jun; 17(3):222-9. PubMed ID: 8599429
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibodies selected to discriminate between malignant melanomas and nevocellular nevi.
Ruiter DJ; Dingjan GM; Steijlen PM; van Beveren-Hooyer M; de Graaff-Reitsma C; Bergman W; van Muijen GN; Warnaar SO
J Invest Dermatol; 1985 Jul; 85(1):4-8. PubMed ID: 3891875
[TBL] [Abstract][Full Text] [Related]
40. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma.
Whiteman DC; Watt P; Purdie DM; Hughes MC; Hayward NK; Green AC
J Natl Cancer Inst; 2003 Jun; 95(11):806-12. PubMed ID: 12783935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
